MA26627A1 - Derives de pyrazole et leurs procedes de preparation - Google Patents

Derives de pyrazole et leurs procedes de preparation

Info

Publication number: MA26627A1
Authority: MA; Morocco
Prior art keywords: pyrazole derivatives; processes; preparation; methods; preparing
Prior art date: 1998-05-05

Application number

MA25567A

Other languages

English (en)

Inventor

Shenvi Labadie Sharada

Brian Sjogren Eric

Xavier Talamas Francisco

Mark Rotstein David

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-05-05

Filing date

1999-05-03

Publication date

2004-12-20

1999-05-03 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2004-12-20 Publication of MA26627A1 publication Critical patent/MA26627A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/52—Oxygen atom in position 3 and nitrogen atom in position 5, or vice versa
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Obesity (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

MA25567A 1998-05-05 1999-05-03 Derives de pyrazole et leurs procedes de preparation MA26627A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US8425098P	1998-05-05	1998-05-05
US12241099P	1999-03-02	1999-03-02

Publications (1)

Publication Number	Publication Date
MA26627A1 true MA26627A1 (fr)	2004-12-20

Family

ID=26770756

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA25567A MA26627A1 (fr)	1998-05-05	1999-05-03	Derives de pyrazole et leurs procedes de preparation

Country Status (22)

Country	Link
EP (1)	EP1075467B1 (fr)
JP (1)	JP3590586B2 (fr)
KR (1)	KR100404256B1 (fr)
CN (1)	CN1147476C (fr)
AT (1)	ATE292118T1 (fr)
AU (1)	AU765030B2 (fr)
BR (1)	BR9911013A (fr)
CA (1)	CA2329065A1 (fr)
DE (1)	DE69924480D1 (fr)
HR (1)	HRP20000724A2 (fr)
HU (1)	HUP0101581A3 (fr)
ID (1)	ID27535A (fr)
IL (1)	IL139169A0 (fr)
MA (1)	MA26627A1 (fr)
NO (1)	NO317985B1 (fr)
NZ (1)	NZ507558A (fr)
PL (1)	PL344004A1 (fr)
RU (1)	RU2000130199A (fr)
TR (1)	TR200003256T2 (fr)
TW (1)	TW593282B (fr)
WO (1)	WO1999057101A1 (fr)
YU (1)	YU67600A (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020156104A1 (en)	1997-06-13	2002-10-24	Jerry L. Adams	Novel pyrazole and pyrazoline substituted compounds
US7301021B2 (en)	1997-07-02	2007-11-27	Smithkline Beecham Corporation	Substituted imidazole compounds
US6316466B1 (en) *	1998-05-05	2001-11-13	Syntex (U.S.A.) Llc	Pyrazole derivatives P-38 MAP kinase inhibitors
US6858617B2 (en)	1998-05-26	2005-02-22	Smithkline Beecham Corporation	Substituted imidazole compounds
ES2212657T3 (es)	1998-11-04	2004-07-16	Smithkline Beecham Corporation	Pirazinas sustituidas piridin-4-il o pirimidin-4-il.
CA2346448A1 (fr) *	1998-12-16	2000-06-22	Warner-Lambert Company	Traitement de l'arthrite a l'aide d'inhibiteurs de la mek
US7125875B2 (en)	1999-04-15	2006-10-24	Bristol-Myers Squibb Company	Cyclic protein tyrosine kinase inhibitors
HUP0202708A3 (en)	1999-04-15	2004-12-28	Bristol Myers Squibb Co	Cyclic protein tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
US6399621B1 (en)	1999-08-10	2002-06-04	American Cyanamid Company	N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1, 5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
US6472528B1 (en) *	1999-08-10	2002-10-29	Neurocrine Biosciences, Inc.	Synthesis of substituted pyrazolopyrimidines
US6485746B1 (en)	2000-08-25	2002-11-26	Neurocrine Biosciences, Inc.	Controlled-release sedative-hypnotic compositions and methods related thereto
US6384221B1 (en)	1999-09-02	2002-05-07	Neurocrine Biosciences, Inc.	Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
WO2001038314A1 (fr)	1999-11-23	2001-05-31	Smithkline Beecham Corporation	Composes de 3,4-dihydro-(1h)quinazolin-2-one utilises comme inhibiteurs de kinase csbp/p38
ES2249309T3 (es)	1999-11-23	2006-04-01	Smithkline Beecham Corp	Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p39 kinasa.
ATE281439T1 (de)	1999-11-23	2004-11-15	Smithkline Beecham Corp	3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
JP2004504266A (ja) *	2000-01-17	2004-02-12	バイエル　アクチェンゲゼルシャフト	置換アリールケトン類
US7235551B2 (en)	2000-03-02	2007-06-26	Smithkline Beecham Corporation	1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
WO2001064669A1 (fr) *	2000-03-03	2001-09-07	Pfizer Products Inc.	Derives d'ether de pyrazole utilises comme agents anti-inflammatoires/analgesiques
CA2876779A1 (fr)	2000-05-12	2001-11-22	Genzyme Corporation	Modulateurs de marquage du tnf-.alpha.
GB0016787D0 (en)	2000-07-07	2000-08-30	Pfizer Ltd	Compounds useful in therapy
CA2419820A1 (fr)	2000-08-17	2002-02-21	Lumera Corporation	Conception et synthese de materiaux optiques non lineaires de pointe destines a des applications electro-optiques
CZ20022642A3 (cs) *	2001-08-27	2003-09-17	Pfizer Products Inc.	Způsob výroby dialkylpyridylboranů
PL373115A1 (en)	2001-08-30	2005-08-08	F.Hoffmann-La Roche Ag	Aminopyrrole compounds as antiinflammatory agents
EP1534282B1 (fr)	2002-07-09	2006-12-27	Boehringer Ingelheim Pharma GmbH & Co.KG	Compositions pharmaceutiques comprenant des agents anticholinergiques etinhibiteurs de p38 kinase pour le traitement des maladies respiratoires
US7268139B2 (en)	2002-08-29	2007-09-11	Scios, Inc.	Methods of promoting osteogenesis
JPWO2004029043A1 (ja)	2002-09-25	2006-01-26	宇部興産株式会社	ピラゾール化合物
RU2381219C2 (ru) *	2003-06-26	2010-02-10	Новартис Аг	ПРОИЗВОДНЫЕ 5-ЧЛЕННЫХ ГЕТЕРОЦИКЛОВ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ p38
PT1641764E (pt)	2003-06-26	2011-10-27	Novartis Ag	Inibidores de p38 quinase a base de heterociclo de 5 elementos
US7244441B2 (en)	2003-09-25	2007-07-17	Scios, Inc.	Stents and intra-luminal prostheses containing map kinase inhibitors
RU2419612C2 (ru) *	2003-12-23	2011-05-27	Астекс Терапьютикс Лимитед	Производные пиразола в качестве модуляторов протеинкиназы
BRPI0511676A (pt) *	2004-05-29	2008-01-08	7Tm Pharma As	uso medicinal de ligandos receptores
US20060035893A1 (en)	2004-08-07	2006-02-16	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es)	2004-12-24	2006-10-06	Boehringer Ingelheim Int	Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
GB0513297D0 (en) *	2005-06-29	2005-08-03	Glaxo Group Ltd	Novel compounds
GB0603684D0 (en) *	2006-02-23	2006-04-05	Novartis Ag	Organic compounds
WO2008000777A2 (fr) *	2006-06-29	2008-01-03	Glaxo Group Limited	Nouveaux composés
GB0621978D0 (en) *	2006-11-03	2006-12-13	Chroma Therapeutics Ltd	Inhibitors of p38 mitogen-activated protein kinase
EP1992344A1 (fr)	2007-05-18	2008-11-19	Institut Curie	P38 alpha comme cible therapeutique pour les maladies associées á une mutation de FGFR3
JP5225470B2 (ja)	2009-08-07	2013-07-03	中外製薬株式会社	アミノピラゾール誘導体
JP2011201794A (ja) *	2010-03-24	2011-10-13	Fujifilm Corp	５−アミノピラゾール誘導体及びその塩の製造方法
JP5620417B2 (ja) *	2011-02-07	2014-11-05	中外製薬株式会社	アミノピラゾール誘導体を含む医薬
KR102191084B1 (ko) *	2013-09-03	2020-12-15	사름 리미티드	약제학적 화합물
TW201609093A (zh)	2013-12-27	2016-03-16	中外製藥股份有限公司	Ｆｇｆｒ門控蛋白變異基因及以其爲標的之醫藥
WO2016204261A1 (fr)	2015-06-17	2016-12-22	中外製薬株式会社	Dérivés d'aminopyrazole
GB201612240D0 (en)	2016-07-14	2016-08-31	Mereo Biopharma 1 Ltd	Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide
GB201612238D0 (en) *	2016-07-14	2016-08-31	Mereo Biopharma 1 Ltd	Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide
WO2018059533A1 (fr) *	2016-09-29	2018-04-05	南京明德新药研发股份有限公司	Inhibiteur de la p38α mapk kinase, son procédé de préparation et son utilisation
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
EP3691620B1 (fr)	2017-10-05	2022-07-27	Fulcrum Therapeutics, Inc.	Inhibiteurs de la kinase p38 réduisant l'expression du gène dux4 et des gènes aval pour le traitement de la fshd
EP3563848A1 (fr) *	2018-04-30	2019-11-06	S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati	Inhibiteurs de la serpine pour le traitement des maladies à prions et de type prion
GB201815699D0 (en) *	2018-09-26	2018-11-07	Mereo Biopharma 1 Ltd	Synthetic method
GB201815695D0 (en) *	2018-09-26	2018-11-07	Mereo Biopharma 1 Ltd	Synthetic method
ES2974842T3 (es) *	2018-11-13	2024-07-01	Novartis Ag	Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de nlrp
CN113166081A (zh)	2018-11-13	2021-07-23	诺华股份有限公司	用于治疗与nlrp活性相关的病症的化合物和组合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69323212T2 (de) *	1992-12-17	1999-05-27	Pfizer Inc., New York, N.Y.	Pyrazole mit crf antagonistischer aktivität

1999
- 1999-04-28 KR KR10-2000-7012375A patent/KR100404256B1/ko not_active Expired - Fee Related
- 1999-04-28 PL PL99344004A patent/PL344004A1/xx not_active Application Discontinuation
- 1999-04-28 HR HR20000724A patent/HRP20000724A2/hr not_active Application Discontinuation
- 1999-04-28 HU HU0101581A patent/HUP0101581A3/hu unknown
- 1999-04-28 CN CNB998060046A patent/CN1147476C/zh not_active Expired - Fee Related
- 1999-04-28 JP JP2000547071A patent/JP3590586B2/ja not_active Expired - Fee Related
- 1999-04-28 WO PCT/EP1999/002879 patent/WO1999057101A1/fr not_active Ceased
- 1999-04-28 BR BR9911013-0A patent/BR9911013A/pt not_active IP Right Cessation
- 1999-04-28 NZ NZ507558A patent/NZ507558A/en unknown
- 1999-04-28 AT AT99923484T patent/ATE292118T1/de not_active IP Right Cessation
- 1999-04-28 IL IL13916999A patent/IL139169A0/xx unknown
- 1999-04-28 AU AU40348/99A patent/AU765030B2/en not_active Ceased
- 1999-04-28 DE DE69924480T patent/DE69924480D1/de not_active Expired - Fee Related
- 1999-04-28 EP EP99923484A patent/EP1075467B1/fr not_active Expired - Lifetime
- 1999-04-28 RU RU2000130199/04A patent/RU2000130199A/ru not_active Application Discontinuation
- 1999-04-28 CA CA002329065A patent/CA2329065A1/fr not_active Abandoned
- 1999-04-28 YU YU67600A patent/YU67600A/sh unknown
- 1999-04-28 ID IDW20002241A patent/ID27535A/id unknown
- 1999-04-28 TR TR2000/03256T patent/TR200003256T2/xx unknown
- 1999-05-03 MA MA25567A patent/MA26627A1/fr unknown
- 1999-05-05 TW TW088107268A patent/TW593282B/zh not_active IP Right Cessation
2000
- 2000-11-02 NO NO20005535A patent/NO317985B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
KR20010043363A (ko)	2001-05-25
ATE292118T1 (de)	2005-04-15
CA2329065A1 (fr)	1999-11-11
KR100404256B1 (ko)	2003-11-01
TW593282B (en)	2004-06-21
RU2000130199A (ru)	2002-11-10
AU4034899A (en)	1999-11-23
EP1075467B1 (fr)	2005-03-30
IL139169A0 (en)	2001-11-25
HRP20000724A2 (en)	2001-06-30
HK1037374A1 (en)	2002-02-08
HUP0101581A2 (hu)	2002-03-28
NZ507558A (en)	2003-08-29
PL344004A1 (en)	2001-09-10
AU765030B2 (en)	2003-09-04
CN1147476C (zh)	2004-04-28
CN1300282A (zh)	2001-06-20
ID27535A (id)	2001-04-12
JP2002513784A (ja)	2002-05-14
BR9911013A (pt)	2001-02-06
EP1075467A1 (fr)	2001-02-14
NO20005535D0 (no)	2000-11-02
DE69924480D1 (en)	2005-05-04
HUP0101581A3 (en)	2002-07-29
TR200003256T2 (tr)	2001-04-20
JP3590586B2 (ja)	2004-11-17
NO317985B1 (no)	2005-01-17
WO1999057101A1 (fr)	1999-11-11
YU67600A (sh)	2003-07-07
NO20005535L (no)	2000-11-02

Publication	Publication Date	Title
MA26627A1 (fr)	2004-12-20	Derives de pyrazole et leurs procedes de preparation
ATE267200T1 (de)	2004-06-15	Bicyclische kinase inhibitoren
BR0014225A (pt)	2002-05-21	Derivados de pirazol
MXPA02011320A (es)	2004-09-10	Derivados de pirazol triciclico como inhibidores de cinasa.
MXPA03010207A (es)	2004-03-10	Nuevas 4-anilinoquinolin-3-carboxamidas.
DE60204452D1 (de)	2005-07-07	Pyrazolo[1,5]pyridinderivate
DE69617273D1 (de)	2002-01-03	Heterocyclisch substituierte cyclopentanderivate.
ATE316083T1 (de)	2006-02-15	Adamantanderivate
DK0503548T3 (da)	1997-11-03	Cykliske ureaderivater, lægemidler indeholdende disse, og fremgangsmåde til deres fremstilling.
ATE300541T1 (de)	2005-08-15	Pyrazolopyridinderivate
DE60004340D1 (de)	2003-09-11	Substituierte 1,4-dihydroindeno[1,2-c]pyrazole als inhibitoren von tyrosinkinase
DE60112742D1 (de)	2005-09-22	Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ATE274515T1 (de)	2004-09-15	Pyrazolopyridinderivate
SE9904128D0 (sv)	1999-11-15	Novel compounds
ECSP992945A (es)	2001-02-21	Derivados de pirazol